PPARβ activation inhibits melanoma cell proliferation involving repression of the Wilms’ tumour suppressor WT1 by Michiels, Jean-François et al.
MOLECULAR AND GENOMIC PHYSIOLOGY
PPARβ activation inhibits melanoma cell proliferation
involving repression of the Wilms’ tumour suppressor WT1
Jean-François Michiels & Christophe Perrin &
Nathalie Leccia & Daniela Massi & Paul Grimaldi &
Nicole Wagner
Received: 19 August 2009 /Revised: 30 November 2009 /Accepted: 15 December 2009 /Published online: 12 January 2010
# The Author(s) 2010. This article is published with open access at Springerlink.com
Abstract Peroxisome proliferator-activated receptors
(PPARs) are ligand-activated transcription factors that
strongly influence molecular signalling in normal and
cancer cells. Although increasing evidence suggests a role
of PPARs in skin carcinogenesis, only expression of
PPARγ has been investigated in human melanoma tissues.
Activation of PPARα has been shown to inhibit the
metastatic potential, whereas stimulation of PPARγ de-
creased melanoma cell proliferation. We show here that the
third member of the PPAR family, PPARβ/δ is expressed in
human melanoma samples. Specific pharmacological acti-
vation of PPARβ using GW0742 or GW501516 in low
concentrations inhibits proliferation of human and murine
melanoma cells. Inhibition of proliferation is accompanied
by decreased expression of the Wilms’ tumour suppressor
1 (WT1), which is implicated in melanoma proliferation.
We demonstrate that PPARβ directly represses WT1 as (1)
PPARβ activation represses WT1 promoter activity; (2) in
chromatin immunoprecipitation and electrophoretic mobil-
ity shift assays, we identified a binding element for PPARβ
in the WT1 promoter; (3) deletion of this binding element
abolishes repression by PPARβ and (4) the WT1 down-
stream molecules nestin and zyxin are down-regulated upon
PPARβ activation. Our findings elucidate a novel mecha-
nism of signalling by ligands of PPARβ, which leads to
suppression of melanoma cell growth through direct
repression of WT1.
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Introduction
The incidence of malignant melanoma has been increasing
steadily worldwide as a consequence of excessive exposure
to sunlight [4, 14]. A sensitive skin phenotype with fair
skin, tendency to burn, inability to tan, the presence of
dysplastic nevi, family history of melanoma and immuno-
suppression are established risk factors [9, 35]. Despite
advancements in early diagnosis and treatment of melano-
ma, morbidity and mortality do not decrease most likely
because of poor understanding of the molecular mecha-
nisms involved in skin repair, skin carcinogenesis and
melanoma growth.
Increasing evidence suggests a role of peroxisome
proliferator-activated receptors (PPARs) in skin formation,
repair and skin carcinogenesis (reviewed in [28]). PPARs
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activated transcription factors [36]. They exist in three
different isoforms termed PPARα,P P A R β/δ and PPARγ.
All PPARs form heterodimers with retinoic X receptors, and,
upon ligand binding, use the basal transcriptional machinery
to regulate gene expression [24]. PPARs are expressed
during normal skin development in the epidermis, hair
follicles and sebaceous glands. In contrast to humans, where
PPARs are also expressed in the adult epidermis, in rodents,
PPARs are down-regulated in the epidermis after birth
(reviewed in [28]). In skin repair, PPARα and PPARβ,b u t
not PPARγ, expression is up-regulated in keratinocytes [27].
In this case, PPARβ is transcriptionally activated via the
TNF-α pathway leading to survival, migration and differen-
tiation of keratinocytes [38].
Several studies suggested that PPAR activation could
interfere with skin carcinogenesis. Mice fed with a PPARα
activator were more resistant to chemically induced
carcinogenesis [40]. In line with this, PPARβ− and
PPARγ-deficient mice were more susceptible against
chronic application of chemical carcinogens [22, 31]. Less
is known about the role of PPARs, especially PPARβ in
melanocytes and melanoma. mRNA expression of all
PPARs has been described in human melanocytes, and
PPARα and γ activators were shown to inhibit cell
proliferation and to stimulate melanin synthesis [21].
Expression of PPARα has been detected in melanoma cells
[11, 16, 17] as well as in human melanoma samples
(Wagner et al., unpublished observation). Pharmacological
PPARα activation has been shown to inhibit the metastatic
potential of melanoma cells, whereas no effect on prolifer-
ation could be observed [11, 16, 17]. In human melanoma
samples, PPARγ expression was demonstrated, and PPARγ
agonists were shown to inhibit the proliferation of human
melanoma cell lines [29]. In addition, PPARβ mRNA
expression had been reported in one melanoma cell line
[15]. However, PPARβ expression in melanoma in vivo
and its possible functional relevance have not been
investigated yet.
Therefore, our study served the purposes to examine (1)
PPARβ expression in melanoma in vivo, (2) to clarify the
functional consequences of PPARβ activation in melanoma
cells and (3) to elucidate possible molecular downstream
pathways of PPARβ activation in melanoma cells.
Here we show that PPARβ is expressed in human
melanoma samples. Pharmacological PPARβ activation in
human and murine melanoma cells at low doses inhibits cell
proliferation without inducing apoptosis. This growth inhibi-
tion of melanoma cells is accompanied by a decrease in the
expression of the Wilms’ tumour suppressor (WT1). Finally,
we demonstrate that PPARβ directly binds to the WT1
promoter and represses its activity, therefore inhibiting the
growth promoting effects of WT1 on melanoma cells.
Materials and methods
Cell culture
Human and mouse melanoma cell lines (A375, accession
number CRL-1676, B16F0, accession number CRL-6322)
were grown in Dulbecco’s modified eagle’sm e d i u m
supplemented with 10% fetal calf serum, 100 IU/ml
penicillin and 100µg/ml streptomycin. Media and reagents
were obtained from Invitrogen (Cergy Pontoise, France).
A375 or B16F0 cells were maintained for 24 h in medium
in the presence of GW0742 (Glaxo Smith Kline, Research
Triangle Park, USA) or GW501516 (Alexis Biochemicals,
Coger S.A., Paris, France) dissolved in dimethyl sulfoxide
(DMSO) at concentrations of 100 or 500 nmol/l. Controls
were treated with vehicle (DMSO) only.
Detection of cell proliferation
A375 and B16F0 cells were split into 96-well dishes,
treated with GW0742, GW501516 or vehicle (DMSO).
Additionally, B16F0 cells were treated with GW0742 in the
presence or absence of a dominant negative PPARβ
isoform (3) and A375 cells after transfection with WT1
expression constructs or PPARβ siRNA constructs. After
24 h, bromodeoxyuridine was added and the cells incubated
for 3 h. Afterwards, cells were fixed and BrdU incorporation
detected using a mouse monoclonal anti-BrdU antibody
followed by incubation with a goat anti-mouse IgG
peroxidase-coupled secondary antibody with TMB as perox-
idase substrate and spectrophotometrical reading of the plates
at 450 nm according to the manufacturer’s instructions
(Millipore, Molsheim, France). Alternatively, 24 h after GW
treatment, cells were methanol fixed and immunohistochem-
icaldetectionofproliferatingcellnuclearantigen(PCNA)was
performed as described [44] with counterstaining of nuclei
using 4',6-diamidino-2-phenylindole (DAPI; Vector Labora-
tories, Burlingame, CA, USA).
Apoptosis assay
Apoptotic cells were detected by TdT-dUTP terminal nick-
end labelling (TUNEL) staining 24 h after GW0742 treatment
using the in situ cell death detection kit (Roche Molecular
Biochemicals, Meylan, France) as described [44].
Sodium dodecyl sulphate-polyacrylamide gel electrophoresis
and Western blot
Total cell lysates were prepared, electrophoresed and
blotted as described [47]. The following antibodies were
used for immunodetection: polyclonal anti-WT1 antibody
from rabbit (C-19, sc-846, Santa Cruz Biotechnology,
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saline (PBS), 2.5% Blotto, 0.05% Tween-20), polyclonal
anti-PPARβ from rabbit (H-74, sc-7197, Santa Cruz
Biotechnology, 1:500), monoclonal anti-nestin from mouse
(MAB5326 and MAB353, Millipore, 1:500), polyclonal
anti-zyxin antibody from rabbit (kind gift of M. Beckerle,
1:1,000), polyclonal anti-GAPDH from goat (L-20,
sc-31915, Santa Cruz Biotechnology, 1:500) and polyclonal
anti-actin from goat (C-11, sc-1615, Santa Cruz Biotech-
nology, 1:500) and peroxidase-coupled goat anti-rabbit
secondary antibody (1:2,000, Vector Laboratories),
peroxidase-coupled horse anti-goat secondary antibody
(1:2,000, Vector Laboratories) and peroxidase-coupled
horse anti-mouse secondary antibody (1:2,000, Vector
Laboratories).
Quantitative RT-PCR
Reverse transcriptase polymerase chain reaction (RT-PCR)
was performed with 2µg of total RNA as described [47].
The following primers were used for PCR amplification:
human WT1 (NCBI accession no. NM005238), 5′-GGACA
AGCCTGTCATTCCTG-3′ (forward primer), 5′-
AAGAAACTGCCATAGCTGGATT-3′ (reverse primer)
and mouse wt1 (NCBI accession no. NM144783), 5′-
CAGATGAACCTAGGAGCTACCTTAAA-3′ (forward
primer), 5′-TGCCCTTCTGTCCATTTCA-3′ (reverse prim-
er). Expression was normalised to the individual levels of
the housekeeping gene GAPDH using the following
primers: human GAPDH (NCBI accession no.
NM002046), 5′-AGCTGTCCCACTTACAGATGC-3′ (for-
ward primer), 5′-CCTTGAAGTCACACTGGTATGG-3′
(reverse primer) and mouse GAPDH (NCBI accession no.
NM008084), 5′-ATTCAACGGCACAGTCAAGG-3′ (for-
ward primer), 5′-TGGATGCAGGGATGATGTTC-3′ (re-
verse primer).
Transient transfection experiments
To investigate the effect of PPARβ expression on WT1
promoter activity, a 767-bp fragment of the WT1 promoter
in the pGl2 basic luciferase expression vector was co-
transfected with PPARβ constructs. A375 and B16F0 cells
were transfected at 60–80% confluency using Fugene 6
reagent (Roche Molecular Biochemicals) or Lipofectamine
2000 (Invitrogen), respectively. About 0.3µg of the reporter
constructs together with 0.1µg of a cytomegalovirus
(CMV)-driven β-galactosidase plasmid, and 1.6µg of the
expression construct encoding PPARβ were transiently co-
transfected and assayed for luciferase- and β-galactosidase
activity as described in detail elsewhere [47]. Alternatively,
the WT1 promoter construct [42] was co-transfected only
with the β-galactosidase reporter plasmid and the cells
cultured for 48 h in the presence of 200 nM GW0742 or
vehicle. The putative PPAR responsive element was deleted
from the WT1 promoter construct using the Quik Change II
site directed mutagenesis kit (Stratagene, Agilent Technol-
ogies, Massy, France) with the following oligonucleotides
5′-CCCCGCAGCTAGCCTGGACATGGGAG-3′ (forward,
reverse primer in the corresponding antisense orientation).
This deletion construct was again co-transfected with the
PPARβ expression construct. To obtain transient over-
expression of WT1, A375 cells were transfected with
plasmids encoding either the WT1(-KTS) or the WT1
(+KTS) splice variant or a combination of both isoforms
(50:50% ratio). The empty expression vector (pCB6+)
served as negative control. To down-regulate PPARβ
expression, siRNA constructs directed against human
PPARβ (sc-36305-SH, Santa Cruz Biotechnology) were
transfected. Subsequently, GW0742 or vehicle (DMSO)
was added to the cultures for a period of 24 h before
Western blot or BrdU incorporation-based proliferation
analysis.
Chromatin immunoprecipitation assay
Chromatin immunoprecipitation (ChIP) assay was per-
formed on B16F0 cells using manufacturer’s instructions
(Millipore). Antibodies (3µg each) against acetylated
histone 3 (rabbit polyclonal antibody, 06-599, Millipore)
and PPARβ (rabbit polyclonal antibody H-74, sc-7197,
Santa Cruz Biotechnology) were used. Normal rabbit serum
served as a negative control and a 1:5 and a 1:10 dilution of
the input sample as positive control. The histone H3
antibody was used to check for preservation of nucleo-
somes at the genomic locus. Following immunoprecipita-
tion, the purified DNA was eluted in 30µl UltraPure
DNase, RNase-free water (Sigma, Saint-Quentin Fallavier,
France). For amplification of purified DNA fragments by
PCR, 1µl of the diluted input DNA or the immunopreci-
pitated DNA’s were mixed with primers, DNase-free water
and Red Taq Ready mix (Sigma). The following primers
were used: WT1 promoter, 5′-CGCAGCTAGCCTCTAG
AATT-3′ (forward), 5′-GCCGTCTAGGTAAGTAATGA-3′
(reverse); 3′UTR, 5′-TTCAAGGTGTCTAGAAAGTC-3′
(forward), 5′-TTACATTAGCAGGCACATAC-3′ (reverse).
PCR products were electrophoresed on a 2% agarose gel
yielding DNA fragments of 215 and 196 bp, respectively.
Electrophoretic mobility shift assays
The putative PPAR responsive element from the WT1
promoter contained the following sequence: 5′-TAGCCTC
TAGAATTCTGGACATGGGA-3′. The PPAR responsive
element from the acyl-CoA oxidase gene (5′-CCCGAACG
TGACCTTTGTCCTGGTCC-3′) served as positive control.
Pflugers Arch - Eur J Physiol (2010) 459:689–703 691Annealed oligonucleotides were
32P-end labelled in a T4
polynucleotide kinase reaction (New England Biolabs,
Ozyme, Saint Quentin Yvelines, France). PPARβ and
RxRα proteins were generated from full-length cDNAs in
pSG5 vector (Stratagene) using the coupled TNT in-vitro-
transcription-translation system (Promega, Charbonnières-les
Bains, France). For supershift assays, the same antibodies as
for the ChIP experiments were used. DNA binding reactions
were performed on ice for 30 min with approximately 20 ng
of proteins in 15µl of a 1× reaction buffer containing 10 mM
Tris–HCl, pH7.5, 50 mM KCl, 50 mM NaCl, 1 mM MgCl2,
1 mM EDTA, 5 mM DTT, 5% glycerol and 0.025 mg/ml
denatured herring sperm DNA. For supershift experiments,
the reaction mixes were pre-incubated for 45 min with the
PPARβ antibodies mentioned above prior to addition of the
labelled oligonucleotides.
Tissue samples and immunohistology
The study adheres to the principles of the Declaration of
Helsinki and to title 45, US code of Federal Regulations,
Part 46, Protection of human subjects. PPARβ immunohis-
tochemical expression was evaluated in normal skin
samples (n=5) and tissue specimens of cutaneous malig-
nant melanomas (seven superficial spreading melanomas,
five nodular melanomas and one subcutaneous melanoma
metastasis), which were obtained from patients who had
undergone surgery at the University of Nice or the
University of Florence Medical School (Table 1). Tissues
were fixed in 10% buffered formalin and paraffin-
embedded. Paraffin sections were dewaxed in xylene,
hydrated in ethanol series and washed in phosphate-
buffered saline. An antigen retrieval method using a
pressure cooker was performed before immunohistochem-
ical staining [33]. Antigen detection was performed using
the EnVision + Dual Link System-HRP from Dako
(Trappes, France) according to the manufacturer’s instruc-
tions using Vector VIP substrate (Vector VIP substrate kit,
SK-4600, Vector Laboratories).
Polyclonal anti-PPARβ from rabbit (H-74, sc-7197,
Santa Cruz Biotechnology) or monoclonal anti-PPARβ
from mouse (MAB 3892, Millipore) were used in a
dilution of 1:100 and 1:500 for the latter in PBS, 0.1%
bovine serum albumin and 0.1% Triton X-100. The
primary antibody was replaced by normal serum in the
negative controls. As an additional positive control to
the PPARβ-positive keratinocytes in the skin samples,
paraffin sections of human colon samples were equally
processed, using DAB as a substrate. Sections were
Table 1 Summary of tumour lesions used for the investigation of PPARβ expression
No. Sex Age Location Histological type Ulceration Clark’s level Breslow thickness (mm)
1 m 82 Shoulder NM Present IV 2
2 m 61 Back NM Present IV 7.5
3 f 65 Arm NM Absent IV 5
4 f 77 Arm NM Absent III 1.2
5 f 70 Back NM Absent IV 3.6
6 m 77 Thigh SSM Present IV 1.3
7 m 87 Shoulder SSM Present IV 2.7
8 f 56 Trunk SSM Present IV 5.5
9 m 52 Back SSM Absent IV 2.1
10 m 70 Abdomen SSM Present IV 3
11 m 69 Back SSM Absent IV 1.7
12 f 47 Leg SSM Absent IV 1.45
13 f 74 Leg Metastasis Absent NA NA
To predict the likelihood of metastatic spread at the time of surgery, Breslow’s tumour thickness, ulceration and Clark’s level are the currently
most accepted prognostic factors [2]
NM nodular melanoma, SSM superficial spreading melanoma, NA not applicable
Fig. 1 PPARβ expression in normal skin, primary and metastatic
melanoma. Representative examples of normal skin (a), nodular
melanoma (b), a melanoma metastasis (c) and superficial spreading
melanoma (d) stained for PPARβ (rabbit polyclonal antibody and VIP
as substrate, purple). Sections were counterstained with haematoxylin to
visualise nuclei. Note the mostly nuclear expression of PPARβ in
keratinocytes, melanocytes and hair follicles and the heterogenous, both
nuclear and cytoplasmatic expression in tumoural melanocytic lesions.
Within the same melanoma metastasis, regions of moderate (c (b)) and
low (c (c)) PPARβ expression coexist. In superficial spreading
melanoma, PPARβ expression dominated in the invasive front of the
tumour (d). Arrows in (d (a)) indicate the position of the high-power
magnifications of the invasive front (d,( b)) and adjacent tissue
(epidermis) with melanocyte atypia (d (c)). No staining could be
observed by replacing the first antibody with normal serum (e). Human
colon sections served as additional positive (f (a)) and negative (f (b))
controls (DAB substrate, brown). Scale bars indicate 50µm
b
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by four independent investigators, three of them experi-
enced dermatopathologists.
For immunofluorescence double-labelling, methanol-
fixed A375 cells or paraffin sections were incubated with
the polyclonal PPARβ antibody and a monoclonal anti-
WT1 antibody from mouse in a 1:100 dilution (clone 6F-
H2, MAB 4234, Millipore). Antigens were visualised
using Cy2 and Cy3 coupled secondary antibodies in a
1 : 1 5 0d i l u t i o n( J a c k s o nI m m u n o - R e s e a r c h ,S u f f o l k ,U K ) .
Slides were viewed under an epifluorescence microscope
(DMLB, Leica, Wetzlar, Germany) connected to a digital
camera (Spot RT Slider, Diagnostic Instruments, Living-
ston, Scotland) with the Spot software (Universal
Imaging, Downingtown, PA, USA).
Statistics
Data are expressed as means±SEM. ANOVA with the
Bonferroni test as post hoc test was used vs. control.
Differences between two groups were tested using the
Mann–Whitney test for non-parametric samples. A p value
less than 0.05 was considered statistically significant.
Results
PPARβ expression in normal skin and melanoma
Several reports focussed on PPARβ expression and
function in keratinocytes whereas to our knowledge,
PPARβ expression in melanocytes and melanoma in vivo
has not been investigated yet. In normal human skin
samples, epidermal keratinocytes, melanocytes, adipo-
cytes, hair follicles, eccrine and sebaceous glands as well
as vascular endothelial cells showed mostly nuclear
immunoreactivity for PPARβ (Fig. 1a). In all melanoma
samples tested (n=13), PPARβ expression could be
observed (Fig. 1b–d). This PPARβ expression was
heterogeneous, with both, a nuclear and granular cyto-
plasmic pattern. Interestingly, in nodular melanomas and
in the melanoma metastasis, we observed an overall
heterogeneous expression pattern within the tumour
lesion, whereas, in all superficial spreading melanomas
tested, less PPARβ expression could be observed. In
superficial spreading melanomas, however, PPARβ ex-
pression was mostly confined to the deeper invasive front,
which might suggest that PPARβ could be connected to
invasion or proliferation of melanoma cells. No staining
could be observed when the first antibody was replaced
with normal serum (Fig. 1e). In addition to the internal
positive control of PPARβ reactive keratinocytes, human
colon sections were stained and depicted the described
expression [20]o fP P A R β in epithelial, mesenchymal and
crypt cells (Fig. 1f).
PPARβ activation inhibits melanoma cell proliferation
To test the functional relevance of PPARβ expression in
melanoma cells, we made use of an in vitro approach
and treated human (A375) and mouse (B16) cells with
low and increasing doses of the specific PPARβ agonists
GW0742 or GW501516. Immunostainings for proliferat-
ing cell nuclear antigen and subsequent counting of
positive cells revealed that already at a concentration of
100 nmol/l GW0742 as well as GW501516 proliferation
of human and mouse melanoma cells was significantly
reduced. This effect was even more pronounced at a
concentration of 500 nmol/l GW0742 or GW501516
(Fig. 2a–d). Higher concentrations of 1µmol/l or 2µmol/l
did not amplify the effect indicating receptor saturation at
500 nmol/l (data not shown). Inhibition of proliferation in
response to pharmacological PPARβ activation was
confirmed in enzyme-linked immunosorbent assay based
5-bromodeoxyuridine (BrdU) incorporation experiments
(Fig. 2e–g). Retroviral transduction of B16 mouse mela-
noma cells with a dominant negative PPARβ isoform
resulted in expression levels of approximately 175% of the
dominant negative form compared to wild-type PPARβ
levels (Fig. 3a). The transduction completely abolished the
anti-proliferative effect of GW0742 (Fig. 3b). The exper-
iment could not be performed on human melanoma cells
because the transduction method for the dominant nega-
tive PPARβ isoform is rodent-specific [3]. Therefore,
constructs containing siRNAs directed against human
PPARβ were transfected in A375 cells. This approach
knocked down PPARβ efficiently as confirmed by
Western blot (Fig. 3c). The siRNA slightly increased
proliferation under control conditions, which might result
from blocking the effects of endogenous PPARβ ligands.
The siRNA against PPARβ restored proliferation in the
presence of different concentrations of GW0742 in A375
melanoma cells.
PPARβ activation is not inducing apoptosis in melanoma
cells
To clarify whether apoptosis might contribute to the
reduced cell number in response to PPARβ stimulation,
we used TdT-dUTP terminal nick-end labelling with
counterstaining of all cell nuclei with DAPI. This was
followed by counting of TUNEL-positive cells and the total
number of cells per optical field. Neither 100 nmol/l
GW0742 or GW501516 nor 500 nmol/l of each of the
specific PPARβ agonists had a significant influence on
apoptosis of melanoma cells (Fig. 4).
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tumour suppressor WT1 and its downstream targets nestin
and zyxin in melanoma cells
As we reported recently that the Wilms’ tumour suppressor
WT1 is associated with high melanoma cell proliferation
[45], we investigated whether this pathway might be
involved in the inhibition of proliferation in response to
PPARβ activation. In quantitative RT-PCR analyses, we
determined that WT1 RNA levels were reduced upon
PPARβ stimulation in human (Fig. 5a) as well as in mouse
(Fig. 5b) melanoma cells. Using Western blot analyses, we
found that although PPARβ expression seems to be lower
in the mouse cells compared to the human cell lines, in both
cases stimulation of the receptor with different concen-
trations of GW0742 did not affect PPARβ protein expres-
Fig. 2 Pharmacological PPARβ activation in melanoma cell lines of
human and murine origin. A375 (human) and B16F0 (mouse)
melanoma cells were treated with different concentrations of two
PPARβ agonists, GW0742, or GW501516, for 24 h. PPARβ activation
inhibits melanoma cell proliferation. PPARβ-agonist-treated cells were
immunostained with an anti-proliferating cell nuclear antigen (PCNA)
antibody and counterstained with DAPI (a (a–c)). Cells in seven
random optical fields were counted and the percentage of PCNA-
positive cells determined (b–d; for each cell line and each agonist,
n=3, P<0.001). Alternatively (e–g), cells were incubated with
5-bromodeoxyuridine (BrdU) followed by immunological detection of
the incorporated BrdU (for each cell line and each agonist, n=4, P<
0.001 for A375 cells and, P<0.05 for B16F0 cells)
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concentration-dependent manner in A375 as well as B16
cells. This observation seems to be relevant for the reduced
proliferation in response to PPARβ stimulation as also
nestin and zyxin protein levels were reduced in response to
GW0742 treatment of human and mouse melanoma cells
(Fig. 5c, d). Both proteins are involved in melanoma cell
proliferation [12, 23, 41] and we showed recently that they
act downstream of WT1 in melanoma cells [45].
PPARβ directly suppresses WT1 in melanoma cells
The down-regulation of WT1 in response to PPARβ
activation raised the possibility that PPARβ might directly
repress WT1. To test this hypothesis, we first analysed
whether both proteins share an overlapping expression in
the same cell types. Immunofluorescent double labelling
showed that as reported, WT1 is not expressed in normal
skin (Fig. 6 a, b) whereas WT1 and PPARβ share a partial
overlapping expression in melanoma samples (Fig. 6 c–f).
The only partial overlap is in agreement with a suppressor
function of one protein on the other factor. Also in A375
melanoma cells, a partial overlap of PPARβ and WT1
could be detected (Fig. 7a). Addition of GW0742 signifi-
cantly repressed the activity of the published WT1
promoter [42] in A375 melanoma cells (Fig. 7b). Transient
co-transfection with a PPARβ expression construct re-
pressed the activity of the WT1 promoter reporter construct
to a comparable extend (Fig. 7c). The combination of
transient co-transfection with a PPARβ expression con-
struct and treatment with GW0742 had no additional effects
on WT1 promoter activity, indicating a saturating effect of
the individual approaches (data not shown). Using in silico
analysis, a sequence region containing a predicted PPAR
responsive element was identified in the WT1 promoter.
This region shows a 62% homology from mouse to human
and a 67% identity between mouse and zebrafish. In
chromatin immunoprecipitation, we show that PPARβ
protein associates with this region, whereas no interaction
could be detected in the 3′UTR of WT1. An antibody
against acetylated histone H3 was used to check for
nucleosome integrity (Fig. 7d). Electrophoretic mobility
Fig. 3 Retroviral transduction of B16F0 melanoma cells with a
dominant negative isoform of PPARβ (PPARβDN) and siRNA
transfection of A375 melanoma cells against PPARβ and subsequent
treatment with a PPARβ agonist GW0742. Western blot for PPARβ
from lysates of B16F0 cells without or with retroviral transduction of
the PPARβDN (a). Note the increase in PPARβ in the transduced
cells reflecting the level of the transduced dominant negative PPARβ
expression. β-actin served as standard. Cells with or without retroviral
transduction with the PPARβDN, were treated with the PPARβ
agonist GW0742 for 24 h. Note that the strong growth inhibitory
effect of GW0742 was completely abolished in the cells expressing
the dominant negative isoform of PPARβ (n=4,P<0.001; b). Western
blot from lysates of A375 cells transfected with siRNA constructs
against human PPARβ (c). Silenced and control cells were treated
with the PPARβ agonist GW0742 for 24 h. Silencing of PPARβ
restores proliferation in the presence of different concentrations of the
agonist (n=8; d)
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oligonucleotide from the WT1 promoter (Fig. 7e). The
published PPARβ binding oligonucleotide from the acyl-
CoA oxidase gene (Aco) [1] served as positive control.
Incubation of the Aco/PPARβ/RxR complex with a
polyclonal PPARβ antibody produced in rabbit supershifted
the retardation band (lane 5 vs. 2). Under our reaction
conditions, the binding affinity of the PPARbeta/RxR
complex to the Aco oligonucleotide seems to be very high
as a large excess of unlabelled competitor was needed to
reduce the signal (lanes 3 and 4). Binding of the PPARbeta/
RxR complex to the oligonucleotide from the WT1
promoter seems to be of lower affinity, as it was easier to
compete. In this case, incubation with the same antibody
decreased the retardation band intensity (lane 10 vs. 7).
Deletion of the identified binding site from the WT1
promoter construct completely abolished repression by co-
transfection of the PPARβ expression construct and by
addition of GW0742 (Fig. 7f). In order to determine
whether normal melanoma cell proliferation is indeed
dependent of WT1 expression, transient transfection experi-
ments with different WT1 splice variants were performed.
Subsequently, the effects of GW0742 administration were
investigated. In A375 melanoma cells over-expressing the
WT1(−KTS), (+KTS) or a combination of both isoforms,
no decrease of WT1 expression on the protein level could
be observed after pharmacological activation of PPARβ
(Fig. 7g). Over-expression of WT1(−KTS) stimulated
nestin expression whereas WT1(+KTS) increased zyxin
protein levels. Combination of both isoforms resulted in
higher nestin and zyxin protein levels. Consistently, WT1
over-expression restored the proliferative potential of the
melanoma cells also in the presence of the PPARβ activator
GW0742 (Fig. 7h).
Discussion
Recently, PPARβ activation became in focus as an
interesting novel approach for the treatment of diabetes,
metabolic syndrome, associated cardiovascular diseases
and a potential tumour therapy [5, 25, 26, 39, 43].
Interestingly, an association between increased risk of
melanoma and high body mass index has been described
[34] whereas exercise appeared to have a protective effect
against melanoma development [37]. Whether PPARβ is
involved in these associations is presently unclear, but
several studies have shown that PPARβ activation mimics
Fig. 4 Apoptosis assay of mel-
anoma cells after pharmaco-
logical PPARβ activation.
TdT-dUTP terminal nick-end
labelling (TUNEL) labelling of
A375 melanoma cells was per-
formed after 24 h of treatment
with either GW0742 or
GW501516. Nuclei were coun-
terstained with DAPI (a). Cells
in ten random fields were
counted and the percentage of
TUNEL-positive cells deter-
mined (b, c; n=4)
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tissue [3, 30, 43]. Our present data using immunohisto-
chemistry on human melanoma samples clearly show that
PPARβ is expressed in these tumours. In normal skin,
PPARβ expression in vivo had been described already
earlier in keratinocytes, hair follicles, sebaceous and
eccrine glands (reviewed in [28]), which is in agreement
with our findings. PPARβ expression in melanocytes had
b e e ns h o w nb yP C Rf r o mc u l t u r e dm e l a n o c y t e si nv i t r o
[21]; however, the expression and function of PPARβ in
melanocytes and melanoma remained elusive. We show
here that PPARβ is expressed in melanocytes and
Fig. 5 Pharmacological PPARβ activation decreases WT1 expression
levelsin melanomacells.Quantitativereversetranscription(RT)-PCRfor
WT1 in A375 (a) and B16F0 (b) melanoma cells treated with GW0742
for 24 h. WT1 expression was normalised to GAPDH (n=8, P<0.01,
P<0.05). Western blot for PPARβ, WT1, nestin and zyxin from lysates
of A375 (c) and B16F0 (d) melanoma cells treated with GW0742. Note
that PPARβ expression remained stable upon pharmacological PPARβ
activation, whereas WT1, nestin and zyxin expression was decreased.
GAPDH and β-actin served as standards (n=8 each)
698 Pflugers Arch - Eur J Physiol (2010) 459:689–703melanoma cells in vivo. In melanomas, the expression
pattern was heterogeneous. Especially in superficial
spreading melanomas, PPARβ w a sc o n f i n e dt ot h e
tumorigenic vertical growth phase component of the
tumour. Moreover, in all melanomas analysed, we ob-
served a nuclear and cytoplasmic granular staining, in
contrast to the normal skin where the expression was
nuclear. At present, it is unclear what functional signifi-
cance this cytoplasmic localisation might have. Interest-
ingly, a similar phenomenon has been described for the
WT1 transcription factor. Shuttling of WT1 between the
nucleus and the cytoplasm has been reported recently [32].
WT1 protein in the cytoplasm interacts with splicing
factors thereby promoting post-transcriptional modifica-
tions [6]. Especially in tumours, WT1 localises predom-
inantly to the cytoplasm [19]. Although PPARβ in
melanoma is localised also to some extent in the
cytoplasm, a potential role as a splicing factor/co-activator
remains to be determined.
To investigate the functional role of PPARβ in melano-
ma, we used different melanoma cell lines of human and
mouse origin and treated the cells independently with two
different highly specific PPARβ agonists. In agreement
with reported results for a breast cancer and another
melanoma cell line [15], we observed an inhibition of
proliferation. This was confirmed independently by label-
ling for PCNA and measurements of BrdU incorporation by
ELISA. Surprisingly, in contrast to the study mentioned
above, we observed this effect already significantly earlier
and at a 100-fold lower dose of the specific PPARβ agonist.
Whether theses discrepancies are due to different cell
culture conditions or variations in the expression levels of
Fig. 6 PPARβ and WT1 co-
localise partially in melanoma.
In normal skin (a, b), no signal
for WT1 could be observed in
immunofluorescence double-
labelling. Partial co-localisation
(yellow)o fP P A R β (Cy2, green)
and WT1 (Cy3, red) could be
detected in melanoma (c–f).
Nuclei were counterstained with
DAPI (blue). Scale bars indicate
50µm
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we observed certain variability in the growth inhibitory
effect of PPARβ activation, the inhibition of proliferation
was reproducible using two different PPARβ agonists in
both cell lines tested. To test whether the observed
inhibition of proliferation was specifically mediated via
PPARβ receptors, we repeated the pharmacological PPARβ
stimulation with GW0742 in B16F0 cells retrovirally
transduced with a dominant negative isoform of PPARβ
and in A375 cells transfected with a siRNA against
PPARβ. Of note, the retrovirally transduced or silenced
cells did not respond to the growth inhibitory effect of
GW0742. Thus, proliferation of melanoma cells seems to
be inhibited specifically by PPARβ activation.
Severalothermoleculeshavebeenimplicatedinmelanoma
cell proliferation, e.g. nestin [12, 23] and zyxin [41]c o r r e l a t e
positively with melanoma proliferation. Recently, we showed
that the Wilms’ tumour suppressor WT1 is important for
melanoma cell proliferation via activation of nestin and
zyxin [45]. WT1 is a transcription factor originally identified
as a tumour suppressor based on mutational inactivation in
nephroblastoma [18]. However, expression of WT1 in
different adult tumours and tumour-derived cell lines has
been described, suggesting that WT1 might also be able to
a c ta sa no n c o g e n e( f o rr e v i e w ,s e e[ 19]).
Interestingly, here we show that pharmacological
PPARβ activation decreases WT1 expression on the RNA
and protein levels. As reported recently using a siRNA
approach, inhibition of WT1 results in reduced melanoma
cell proliferation without affecting apoptosis [45], which
was confirmed in the present study. To test for a possible
direct regulation of WT1 by PPARβ, we performed double-
labelling experiments. The only partial overlapping expres-
sion pattern of PPARβ and WT1 in melanoma in vivo and
in melanoma cells in vitro and our observed down-
regulation of WT1 in response to PPARβ activation
suggested that PPARβ might act as a repressor of WT1.
Several lines of evidence confirmed that WT1 represents a
relevant target of PPARβ in melanoma cells. First, transient
transfection experiments showed that the activity of the
WT1 promoter was significantly inhibited by pharmaco-
logical PPARβ activation. Second, PPARβ co-transfection
also inhibited the activity of the WT1 promoter indicating a
specific effect of PPARβ on the WT1 promoter. Third, in
chromatin immunoprecipitation experiments we confirmed
direct binding of PPARβ to the WT1 promoter sequence,
but not to the 3′-UTR of WT1. Fourth, in electrophoretic
mobility shift assays, we identified a 26 bp element in the
WT1 promoter, which directly binds to the PPARβ/RxRα
protein complex. Finally, mutation of the identified binding
site abolished repression by PPARβ or the agonist
GW0742.
Interestingly, over-expression of WT1 in melanoma cells
restored the proliferative potential of these tumour cells
overcoming the growth inhibitory effects of PPARβ
activation. This confirms our recent finding that WT1 is
required for melanoma cell proliferation [45].
To test whether PPARβ activation affected not only
WT1, but also WT1 downstream target genes, we analysed
protein levels of zyxin and nestin [45], which are both
involved in melanoma cell proliferation. The dose-
dependent reduction of nestin and zyxin upon pharmaco-
logical PPARβ activation suggests that not only WT1, but
also its downstream signalling in melanoma cells is
consistently affected by PPARβ stimulation. Transient
over-expression of WT1(−KTS) resulted in upregulation
of nestin, which is consistent with a previous report [46],
whereas over-expression of WT1(+KTS) stimulated zyxin
expression. Whether zyxin represents a direct target of
WT1(+KTS) remains to be determined in future studies. As
nestin [12, 23]a n dz y x i n[ 41] are both involved in
melanoma cell proliferation, it is not surprising that over-
expression of either WT1(−KTS) or WT1(+KTS) restored
melanoma cell proliferation. In these WT1 over-expression
Fig. 7 PPARβ represses WT1. Co-localisation of PPARβ (Cy2,
green) and WT1 (Cy3, red) in A375 melanoma cells (a). Nuclei were
counterstained with DAPI (blue). Scale bars indicate 50µm. b
Transient transfection of the WT1 promoter in a luciferase vector in
the presence of vehicle or 200 nM GW0742 in A375 cells. Luciferase
activities were normalised for the activity of co-transfected β-
galactosidase (n=8, P<0.01). c Transient co-transfections of a WT1
promoter construct together with a PPARβ expression construct in
A375 melanoma cells (n=12, P<0.01). d Chromatin immunoprecip-
itation to analyse PPARβ protein interaction with WT1 regulatory
elements. PPARβ protein binds to the WT1 promoter (upper panel),
but not to the 3’-untranslated region (UTR) of WT1 (lower panel).
Input DNA and immunoprecipitates obtained with acetylated histone 3
antibody served as positive controls. Negative controls were
performed with normal serum instead of specific antibodies and with
DNase-free water for the PCR. e Electrophoretic mobility shift assay
demonstrating binding of the PPARβ/RXRα complex to the predicted
consensus element of the WT1 promoter (lane 7). Unlabelled
oligonucleotide from the acyl-CoA oxidase gene in the indicated
molar excess was used as competitor (lanes 3, 4, 8 and 9). Supershift
assays were performed by incubating the binding reactions with a
polyclonal anti-PPARβ antibody (Ab rabbit, lanes 5 and 10). An
oligonucleotide from the acyl-CoA oxidase gene served as positive
control [1]. f Transient co-transfections of a WT1 construct with
deletion of the identified 26 bp consensus motif together with PPARβ
expression constructs or in the presence of 200 nM GW0742 in A375
melanoma cells (n=12). Note that the 26 bp deletion abolished
transactivation of the WT1 promoter by PPARβ or GW0742. g
Western blot for WT1, nestin and zyxin from lysates of A375 cells
transiently transfected with the WT1 (−KTS) or (+KTS) variant or a
combination of both isoforms in a 50:50% ratio. Cells were
subsequently treated with vehicle or 100 nM GW0742. Note that the
decrease of WT1 expression by pharmacological PPARβ activation is
abolished in the WT1 over-expressing cells. β-actin served as
standard. h BrdU incorporation assay of the WT1 over-expressing
cells, without or with pharmacological PPARβ activation. The growth
inhibitory effect of GW0742 is abolished in the cells over-expressing
any of the WT1 splice variants (n=4, P<0.001)
R
Pflugers Arch - Eur J Physiol (2010) 459:689–703 701experiments, pharmacological PPARβ activation did not
have an effect on melanoma cell proliferation, since the
different WT1 expression constructs are under control of a
CMV promoter, but did not include the WT1 promoter
sequence.
Although some molecules regulating WT1 have been
reported, e.g. Pax2/8 [7, 13], Pea3 [10], NF-κB[ 8]o r
Hif-1α [42], the repression of WT1 by PPARβ and
subsequent inhibition of melanoma cell proliferation is of
special interest, as specific pharmacological activators of
PPARβ already exist. Whether pharmacological PPARβ
activation in vivo is sufficient to inhibit melanoma growth
will be clarified in further studies. Nevertheless, it is likely
that PPARβ activation might inhibit melanoma growth as
it has been shown that colon carcinoma cells express
PPARβ; and colon carcinogenesis could be inhibited by
the PPARβ agonist GW0742 [26].
In summary, we have shown here that PPARβ is
expressed in melanocytes and melanoma in vivo. PPARβ
activation inhibits melanoma cell proliferation, which
involves transcriptional repression of WT1.
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